JP6860477B2 - Ｒｐｌ５５４を含む液体吸入製剤 - Google Patents

Ｒｐｌ５５４を含む液体吸入製剤 Download PDF

Info

Publication number
JP6860477B2
JP6860477B2 JP2017514346A JP2017514346A JP6860477B2 JP 6860477 B2 JP6860477 B2 JP 6860477B2 JP 2017514346 A JP2017514346 A JP 2017514346A JP 2017514346 A JP2017514346 A JP 2017514346A JP 6860477 B2 JP6860477 B2 JP 6860477B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
rpl554
concentration
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017514346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528479A (ja
JP2017528479A5 (enExample
Inventor
リオネル スパーゴ、ピーター
リオネル スパーゴ、ピーター
ジェームズ フレンチ、エドワード
ジェームズ フレンチ、エドワード
エイ ヘイウッド、フィリップ
エイ ヘイウッド、フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of JP2017528479A publication Critical patent/JP2017528479A/ja
Publication of JP2017528479A5 publication Critical patent/JP2017528479A5/ja
Application granted granted Critical
Publication of JP6860477B2 publication Critical patent/JP6860477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017514346A 2014-09-15 2015-09-15 Ｒｐｌ５５４を含む液体吸入製剤 Active JP6860477B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1416274.7 2014-09-15
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GB1504662.6 2015-03-19
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
PCT/GB2015/052668 WO2016042313A1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018238014A Division JP6795574B2 (ja) 2014-09-15 2018-12-20 Ｒｐｌ５５４を含む液体吸入製剤

Publications (3)

Publication Number Publication Date
JP2017528479A JP2017528479A (ja) 2017-09-28
JP2017528479A5 JP2017528479A5 (enExample) 2018-10-25
JP6860477B2 true JP6860477B2 (ja) 2021-04-14

Family

ID=54196992

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017514346A Active JP6860477B2 (ja) 2014-09-15 2015-09-15 Ｒｐｌ５５４を含む液体吸入製剤
JP2018238014A Active JP6795574B2 (ja) 2014-09-15 2018-12-20 Ｒｐｌ５５４を含む液体吸入製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018238014A Active JP6795574B2 (ja) 2014-09-15 2018-12-20 Ｒｐｌ５５４を含む液体吸入製剤

Country Status (27)

Country Link
US (2) US9956171B2 (enExample)
EP (3) EP3494962B1 (enExample)
JP (2) JP6860477B2 (enExample)
KR (1) KR102379309B1 (enExample)
CN (3) CN111249260B (enExample)
AU (3) AU2015316592B2 (enExample)
CA (1) CA2959943C (enExample)
CY (3) CY1120264T1 (enExample)
DK (3) DK3494962T3 (enExample)
ES (3) ES2670025T3 (enExample)
HK (1) HK1249415B (enExample)
HR (3) HRP20180833T1 (enExample)
HU (3) HUE055527T2 (enExample)
IL (1) IL250895B (enExample)
LT (3) LT3494962T (enExample)
MX (1) MX2017003102A (enExample)
MY (1) MY196072A (enExample)
NO (1) NO3193835T3 (enExample)
PH (1) PH12017500479B1 (enExample)
PL (3) PL3494962T3 (enExample)
PT (3) PT3332767T (enExample)
RS (3) RS58897B1 (enExample)
RU (1) RU2699995C2 (enExample)
SG (1) SG11201701854WA (enExample)
SI (3) SI3494962T1 (enExample)
SM (3) SMT201800242T1 (enExample)
WO (1) WO2016042313A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2682105T3 (es) 2014-05-12 2018-09-18 Verona Pharma Plc Nuevo tratamiento
ES2670025T3 (es) * 2014-09-15 2018-05-29 Verona Pharma Plc Formulación para inhalación líquida que comprende RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
HK1251593A1 (zh) 2015-07-24 2019-02-01 豪夫迈‧罗氏有限公司 Bace1抑制剂肽
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
CN114929700B (zh) * 2020-01-15 2024-11-22 正大天晴药业集团股份有限公司 三并环类pde3/pde4双重抑制剂化合物的药物组合物
GB202002786D0 (en) * 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CA3263545A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc LIQUID PHARMACEUTICAL COMPOSITION
WO2024033625A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) for increasing trough lung function
CN119923263A (zh) * 2022-10-28 2025-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
WO2025003643A1 (en) * 2023-06-26 2025-01-02 Verona Pharma Plc Particulate composition comprising ensifetrine
US20250073240A1 (en) * 2023-09-06 2025-03-06 Verona Pharma Plc New treatment
WO2025168546A1 (en) * 2024-02-05 2025-08-14 Verona Pharma Plc Ensifentrine for the treatment of copd
US20250249007A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease
US20250249008A1 (en) * 2024-02-07 2025-08-07 Verona Pharma Plc Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
WO1999018971A1 (en) 1997-10-09 1999-04-22 Schering Corporation Mometasone furoate suspensions for nebulization
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
PT1165558E (pt) 1999-03-31 2004-02-27 Vernalis Ltd Derivados de pirimido¬6,1-a|isoquinolina-4-ona
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0122031D0 (en) * 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
US7579505B2 (en) 2004-12-17 2009-08-25 Cipla Limited Crystalline levosalbutamol sulphate and polymorphic forms thereof
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
WO2011161018A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
AU2011288497B2 (en) 2010-08-09 2016-01-21 Verona Pharma Plc Crystalline form of pyrimido[6,1-a]isoquinolin-4-one compound
CN103732213A (zh) * 2011-06-07 2014-04-16 帕里昂科学公司 治疗方法
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
AU2014229739B2 (en) 2013-03-15 2018-07-26 Verona Pharma Plc Drug combination
KR102378132B1 (ko) * 2014-03-11 2022-03-24 엘지전자 주식회사 무선 통신 시스템에서 장치 대 장치 단말의 디스커버리 신호 전송 방법 및 장치
ES2682105T3 (es) 2014-05-12 2018-09-18 Verona Pharma Plc Nuevo tratamiento
ES2670025T3 (es) * 2014-09-15 2018-05-29 Verona Pharma Plc Formulación para inhalación líquida que comprende RPL554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
PL3494962T3 (pl) 2021-12-06
NZ767296A (en) 2024-01-26
KR102379309B1 (ko) 2022-03-28
HUE045303T2 (hu) 2019-12-30
EP3332767A1 (en) 2018-06-13
MY196072A (en) 2023-03-13
DK3494962T3 (da) 2021-06-21
BR112017005050A2 (pt) 2018-01-23
HUE038433T2 (hu) 2018-10-29
JP2017528479A (ja) 2017-09-28
AU2020203081A1 (en) 2020-05-28
HUE055527T2 (hu) 2021-12-28
PT3332767T (pt) 2019-06-27
EP3332767B1 (en) 2019-03-20
SMT202100479T1 (it) 2021-09-14
CY1120264T1 (el) 2019-07-10
US20180369139A1 (en) 2018-12-27
US20170239178A1 (en) 2017-08-24
PT3193835T (pt) 2018-03-27
PL3332767T3 (pl) 2019-10-31
EP3193835A1 (en) 2017-07-26
IL250895A0 (en) 2017-04-30
AU2018286571B2 (en) 2020-04-02
SI3332767T1 (sl) 2019-07-31
WO2016042313A1 (en) 2016-03-24
CN111249260B (zh) 2023-01-10
EP3494962A1 (en) 2019-06-12
HRP20180833T1 (hr) 2018-06-29
US10945950B2 (en) 2021-03-16
IL250895B (en) 2019-08-29
HRP20191122T1 (hr) 2019-09-20
SI3494962T1 (sl) 2021-09-30
RU2017108432A (ru) 2018-10-17
PH12017500479B1 (en) 2021-07-21
AU2015316592B2 (en) 2020-04-02
SMT201800242T1 (it) 2018-07-17
AU2020203081B2 (en) 2021-08-05
CN106794157A (zh) 2017-05-31
PL3193835T3 (pl) 2018-07-31
NZ767295A (en) 2024-01-26
JP6795574B2 (ja) 2020-12-02
CN106794157B (zh) 2021-03-09
EP3193835B1 (en) 2018-03-07
RS58897B1 (sr) 2019-08-30
JP2019069978A (ja) 2019-05-09
CN110051627A (zh) 2019-07-26
CN111249260A (zh) 2020-06-09
CA2959943A1 (en) 2016-03-24
LT3193835T (lt) 2018-06-11
RU2017108432A3 (enExample) 2019-04-01
SMT201900340T1 (it) 2019-07-11
AU2015316592A1 (en) 2017-03-23
CY1121698T1 (el) 2020-07-31
RS57227B1 (sr) 2018-07-31
SG11201701854WA (en) 2017-04-27
DK3332767T3 (da) 2019-06-24
MX2017003102A (es) 2017-06-14
KR20170054406A (ko) 2017-05-17
HRP20211035T1 (hr) 2021-09-17
RS62252B1 (sr) 2021-09-30
DK3193835T3 (en) 2018-05-07
SI3193835T1 (en) 2018-06-29
CY1124546T1 (el) 2022-07-22
HK1249415B (en) 2019-11-22
NZ729796A (en) 2024-01-26
ES2730810T3 (es) 2019-11-12
LT3332767T (lt) 2019-06-25
US9956171B2 (en) 2018-05-01
RU2699995C2 (ru) 2019-09-12
PT3494962T (pt) 2021-06-22
EP3494962B1 (en) 2021-05-26
NO3193835T3 (enExample) 2018-08-04
ES2670025T3 (es) 2018-05-29
CA2959943C (en) 2022-08-16
AU2018286571A1 (en) 2019-01-24
PH12017500479A1 (en) 2017-07-31
LT3494962T (lt) 2021-07-26
ES2875584T3 (es) 2021-11-10

Similar Documents

Publication Publication Date Title
JP6795574B2 (ja) Ｒｐｌ５５４を含む液体吸入製剤
HK1249415A1 (en) Liquid inhalation formulation comprising rpl554
EA012388B1 (ru) Водные суспензии циклесонида для аэрозольного распыления
DK2704724T3 (en) Improved suspension formulation of beclomethasone dipropionate for administration by inhalation
HK40007474B (en) Liquid inhalation formulation comprising rpl554
HK40007474A (en) Liquid inhalation formulation comprising rpl554
HK1233919B (en) Liquid inhalation formulation comprising rpl554
HK1233919A1 (en) Liquid inhalation formulation comprising rpl554
KR20180030399A (ko) 네뷸라이저용 조성물
BR112017005050B1 (pt) Composições farmacêuticas líquidas, nebulizador e usos da composição farmacêutica líquida
HK1098486B (en) Aqueous suspensions of ciclesonide for nebulisation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170419

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20191105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210326

R150 Certificate of patent or registration of utility model

Ref document number: 6860477

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250